Allelica, Inc

Allelica develops clinical Polygenic Risk Score (PRS) tests to prevent cardiovascular disease and cancer. Our diagnostics are used by leading healthcare institutions in the US and internationally to identify high-risk individuals who benefit from personalized prevention and screening plans. We also operate through a decentralized model, enabling clinical genetics laboratories to develop and deliver their own PRS-based diagnostics with confidence. Working with leaders in the field, such as Baylor College of Medicine, we have set the industry standard for developing clinical PRS tests, ensuring quality and regulatory compliance at every step. Our infrastructure supports both cloud-based and on-premise implementation, empowering labs and biopharma companies to perform validated PRS analysis across multiple ancestries. Allelica’s research has been published in Circulation, Nature Communication, Journal of the American Heart Association and presented at premier conferences. Our mission is to reduce human suffering through better, data-driven medicine. We believe that empowering physicians with accurate risk stratification tools is essential to advancing primary prevention, improving patient outcomes and reducing healthcare costs.